BiotechTube
TellBio

TellBio

Cambridge, United States· Est.
tellbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17M

Overview

TellBio is a private, development-stage biotech leveraging a proprietary microfluidic platform to isolate and analyze circulating tumor cells (CTCs), licensed from Massachusetts General Hospital. Its core diagnostic system, TellDx, is deployed as a research tool globally, with data informing a complementary therapeutic pipeline, TellRx. The company aims to address critical unmet needs in early cancer detection, monitoring metastasis, and developing targeted therapies, positioning itself as a revenue-generating entity through its research tools while advancing toward clinical applications.

Oncology

Technology Platform

Proprietary microfluidic system for the label-free, tumor-agnostic isolation and analysis of viable circulating tumor cells (CTCs), enabling liquid biopsy diagnostics and therapeutic target discovery.

Funding History

2
Total raised:$17M
Series A$12M
Seed$5M

Opportunities

The large and growing liquid biopsy market presents a major opportunity for a minimally invasive, tumor-agnostic monitoring tool like TellDx.
Furthermore, successfully developing therapeutics based on unique CTC biology could address the critical unmet need of treating metastatic disease, a high-value market segment.

Risk Factors

Key risks include intense competition in the liquid biopsy space, the high failure rate of novel therapeutic development, and the significant capital required to clinically validate the diagnostic platform and advance the drug pipeline.
Regulatory and reimbursement hurdles for new diagnostic paradigms also pose substantial challenges.

Competitive Landscape

TellBio competes in the crowded liquid biopsy market against large, commercial players like Guardant Health and Exact Sciences, as well as other CTC-focused companies. Its differentiation lies in its tumor-agnostic approach to isolating viable CTCs and its integrated therapeutic discovery platform, but it must prove clinical utility and scalability to gain significant market share.

More companies in Diagnostics & Precision Medicine →More companies in United States →